These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27783030)

  • 1. New anti-hepatitis B virus drugs under development and evaluation.
    Pan J; Tong S; Kang L; Tang J
    Curr Opin Infect Dis; 2016 Dec; 29(6):632-638. PubMed ID: 27783030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor.
    Kim SY; Kim H; Kim SW; Lee NR; Yi CM; Heo J; Kim BJ; Kim NJ; Inn KS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Chronic Hepatitis B Virus Infection.
    Bertoletti A; Le Bert N
    Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for the treatment of hepatitis B.
    Fung J; Lai CL; Seto WK; Yuen MF
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):183-93. PubMed ID: 26940510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years.
    Liu B; Wen X; Huang C; Wei Y
    Int J Biochem Cell Biol; 2013 Sep; 45(9):1987-96. PubMed ID: 23819994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel viral and host targets to cure hepatitis B.
    Ko C; Michler T; Protzer U
    Curr Opin Virol; 2017 Jun; 24():38-45. PubMed ID: 28433762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
    Revill P; Locarnini S
    Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors.
    Zhang BY; Chai DP; Wu YH; Qiu LP; Zhang YY; Ye ZH; Yu XP
    Curr Drug Targets; 2019; 20(16):1636-1651. PubMed ID: 31362671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.
    Zoulim F
    Antiviral Res; 2004 Oct; 64(1):1-15. PubMed ID: 15451174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in Development for Hepatitis B.
    Dawood A; Abdul Basit S; Jayaraj M; Gish RG
    Drugs; 2017 Aug; 77(12):1263-1280. PubMed ID: 28660478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic agents for chronic hepatitis B.
    Brahmania M; Feld J; Arif A; Janssen HL
    Lancet Infect Dis; 2016 Feb; 16(2):e10-21. PubMed ID: 26795693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host factor-targeted hepatitis B virus therapies.
    Gehring A; Bertoletti A; Tavis JE
    Intervirology; 2014; 57(3-4):158-62. PubMed ID: 25034483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.